FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a chimeric antigenic receptor (CAR) that elicits an antigen-specific response against CD22 when binding CAR to CD22, a nucleic acid encoding it, as well as a vector and a host cell containing said nucleic acid. Also disclosed is a pharmaceutical composition for treating or preventing cancer in a mammal, as well as a method of treating or preventing cancer in a mammal using said CAR. Invention also relates to the use of said host cell for the manufacture of a medicament for the treatment or prevention of cancer, where the cancer expresses CD22, as well as for the manufacture of a composition for detecting cancer, where the cancer expresses CD22.
EFFECT: invention enables to effectively treat or prevent cancer in a mammal.
31 cl, 6 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC ANTIGEN RECEPTORS M971 | 2018 |
|
RU2770411C1 |
| CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR THYMIC STROMAL LYMPHOPOIETIN RECEPTOR, AND METHODS FOR USE THEREOF | 2014 |
|
RU2701346C1 |
| CHIMERIC ANTIGENIC RECEPTORS TO CD22 | 2012 |
|
RU2644243C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN | 2013 |
|
RU2650805C2 |
| EXOTOXIN A PSEUDOMONAS WITH LESS IMMUNOGENIC T-AND/OR B-CELL EPITHOPES | 2012 |
|
RU2627216C2 |
| MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
